Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile
A Randomized, Evaluator-blinded, Parallel Group, Comparator-controlled, Multicenter Study to Evaluate the Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Project Manager
- Phone Number: 817-961-5000
- Email: aestheticclinicaltrials@galderma.com
Study Contact Backup
- Name: Study Director Galderma R&D
- Phone Number: 817-961-5000
- Email: aestheticclinicaltrials@galderma.com
Study Locations
-
-
-
San Juan, Puerto Rico, 00917
- Galderma Research Site
-
-
-
-
California
-
Los Angeles, California, United States, 90025
- Galderma Research Site
-
Manhattan Beach, California, United States, 90266
- United States, California
-
-
Connecticut
-
Westport, Connecticut, United States, 06880
- Galderma Research Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- Galderma Research Site
-
Coral Gables, Florida, United States, 33143
- Galderma Research Site
-
-
Georgia
-
Alpharetta, Georgia, United States, 30022
- Galderma Research Site
-
Atlanta, Georgia, United States, 30331
- Galderma Research Site
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- Galderma Research Site
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States, 02467
- Galderma Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Galderma Research Site
-
-
Texas
-
Pflugerville, Texas, United States, 78660
- Galderma Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males or non-pregnant, non-breastfeeding females, 22 years of age or older
- Intent to receive treatment for augmentation and correction of retrusion in the chin region.
Exclusion Criteria:
- Known/previous allergy of hypersensitivity to any injectable hyaluronic acid (HA) gel or gram-positive bacterial proteins.
- Known/previous allergy or hypersensitivity to local anesthetics, e.g., lidocaine or other amide-type anesthetics.
- Previous or present multiple severe allergies or severe allergies, such as manifested by anaphylaxis or angioedema or family history of angioedema.
- Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from the subnasale.
- Any previous aesthetic procedures or implants
- Presence of any disease or lesion near or on the area to be treated.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: New Dermal Filler for indication: Restylane Lyft with Lidocaine
hyaluronic acid dermal filler
|
hyaluronic acid
|
|
Active Comparator: Active Comparator: FDA approved Dermal Filler: Juvederm Voluma XC
hyaluronic acid dermal filler
|
hyaluronic acid
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in the Blinded Evaluators' Live Assessment Using the Galderma Chin Retrusion Scale (GCRS) at Month 3
Time Frame: Baseline (last non-missing observation prior to the first administration of study product) and Month 3
|
GCRS is a validated 4-grade scale to assess the chin retrusion from no retrusion (0) to severe retrusion (3) which was described as follows; "0- No retrusion", "1- Mild retrusion", "2- Moderate retrusion", "3- Severe retrusion".
Higher scores indicated more severity.
Least squares (LS) mean, and 95 percent (%) confidence interval (CI) were obtained from a general linear mixed random intercept model with treatment group and baseline Galderma Chin Retrusion Scale score as fixed factors.
|
Baseline (last non-missing observation prior to the first administration of study product) and Month 3
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Responder Rate Based on the Blinded Evaluator's Live Assessment Using the GCRS at Months 6, 9, and 12
Time Frame: At Months 6, 9, and 12
|
GCRS is a validated 4-grade scale to assess the chin retrusion from no retrusion (0) to severe retrusion (3) which was described as follows; "0- No retrusion", "1- Mild retrusion", "2- Moderate retrusion", "3- Severe retrusion".
Higher scores indicated more severity.
Responder rate was defined as percentage of participants with an improvement of at least one grade on the GCRS from baseline.
95% CI was calculated using Clopper-Pearson method.
|
At Months 6, 9, and 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Study Director, Galderma R&D
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Anesthetics, Local
- Anesthetics
- Central Nervous System Depressants
- Sensory System Agents
- Anti-Arrhythmia Agents
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Membrane Transport Modulators
- Lidocaine
Other Study ID Numbers
Other Study ID Numbers
- 43USCH2208
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.